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The dual potential to promote tolerance or inflammation to self-antigens makes den-
dritic cells (DCs) fundamental players in autoimmunity. Previous results have shown 
that stimulation of dopamine receptor D5 (DRD5) in DCs potentiates their inflammatory 
behaviour, favouring the development of experimental autoimmune encephalomyelitis 
(EAE). Here, we aimed to decipher the underlying mechanism and to test its relevance in 
multiple sclerosis (MS) patients. Our data shows that DRD5-deficiency confined to DCs 
in EAE mice resulted in reduced frequencies of CD4+ T-cell subsets with inflammatory 
potential in the central nervous system, including not only Th1 and Th17 cells but also 
granulocyte-macrophage colony-stimulating factor producers. Importantly, ex vivo 
depletion of dopamine from DCs resulted in a dramatic reduction of EAE severity, high-
lighting the relevance of an autocrine loop promoting inflammation in vivo. Mechanistic 
analyses indicated that DRD5-signalling in both mouse DCs and human monocytes 
involves the attenuation of signal transducer and activator of transcription 3-activation, 
a transcription factor that limits the production of the inflammatory cytokines interleukin 
(IL)-12 and IL-23. Furthermore, we found an exacerbated expression of all dopamine 
receptors in peripheral blood pro-inflammatory monocytes obtained from MS patients. 
These findings illustrate a novel mechanism by which myeloid antigen-presenting cells 
may trigger the onset of their inflammatory behaviour promoting the development of 
autoimmunity.
Keywords: multiple sclerosis, experimental autoimmune encephalomyelitis, antigen-presenting cells, cD4+ 
T cells, dopamine
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inTrODUcTiOn
T-cell mediated immunity can respond to a huge variety of 
foreign and self-antigens as a result of a wide repertoire of T-cell 
receptors generated by genomic recombination. To avoid auto-
immune responses, self-reactive T-cells have to be eliminated or 
rendered tolerant, a process in which dendritic cells (DCs) play a 
fundamental role. Indeed, constitutive depletion of DCs leads to 
spontaneous fatal autoimmunity (1). On the other hand, during 
onset of autoimmunity DCs seem to be critical for priming of 
self-reactive T-cells that escape of tolerance induction (2). This 
dual potential of DCs promoting tolerance or inducing inflam-
mation to self-antigens makes these cells fundamental players in 
the physiopathology of autoimmunity.
Unravelling molecular mechanisms controlling the switch 
between the tolerogenic and the pro-inflammatory behaviours 
of DCs results of pivotal importance to understand the develop-
ment of autoimmune disorders. In this regard, a master inducer 
of the pro-inflammatory potential of DCs is the transcription 
factor nuclear factor kappa B (NF-κB), which may be activated 
by the integration of many different inflammatory cues, includ-
ing pro-inflammatory cytokines, pattern-recognition receptors 
stimulation, and the inflammasome (3–5). Importantly, NF-κB 
activation in DCs has been associated with the production of 
interleukin (IL)-12 and IL-23, which are, respectively, involved 
in the induction of Th1 and Th17 immunity (6, 7). Conversely, 
by inducing the expression of anti-inflammatory mediators, such 
as IL-10, TGF-β, and retinaldehyde dehydrogenase, the activa-
tion of β-catenin has been described to play a pivotal role in the 
acquisition of the tolerogenic potential by DCs (8, 9). Another 
key regulator of DCs behaviour is the transcription factor signal 
transducer and activator of transcription 3 (STAT3), which upon 
phosphorylation inhibits the NF-κB-mediated induction of IL-12 
and IL-23, attenuating the inflammatory potential of these cells 
(10, 11).
Previous evidence suggested that Th1 as well as Th17 cells are 
the phenotypes of autoreactive T-cells involved in autoimmun-
ity, including multiple sclerosis (MS) and its mouse model, the 
experimental autoimmune encephalomyelitis (EAE) (12, 13). 
Despite there are several studies indicating that Th17 and Th1 cells 
infiltrate the central nervous system (CNS) during the course of 
EAE development, more recent studies have shown that mice 
bearing IL-17- or interferon (IFN)-γ-deficient CD4+ T-cells, still 
developed EAE, although with decreased severity. In this regard, 
irrespective of the secretion of IL-17 and IFN-γ, the production 
of granulocyte-macrophage colony-stimulating factor (GM-CSF) 
by autoreactive CD4+ T-cells was essential for the development 
of EAE (14, 15). Thus, the pro-inflammatory cytokines IL-17, 
IFN-γ, and GM-CSF produced by CD4+ T-cells contribute to 
the development of EAE, although the latter plays a major role 
(14, 16). The production of this cytokine is induced in CD4+ 
T-cells by the concerted action of IL-23 and IL-12 (14, 15, 17). 
Thereby DCs, by means of the secretion of IL-12 and IL-23 could 
regulate the production of GM-CSF by CD4+ T-cells. On the 
other hand, CD4+ regulatory T-cells (Tregs) infiltrate progres-
sively into the CNS starting on the disease onset. However, the 
generation and the suppressive activity of CNS-infiltrated Tregs 
are impaired by γδT-cells (18). This latter T-cell subset infiltrates 
the CNS during EAE, starting at the disease onset, reaching the 
highest cell number at the peak of disease manifestation, and 
then progressively disappearing from the CNS, thus correlating 
with the time-course of EAE manifestation (18). γδT-cells inhibit 
CD4+ Tregs function and produce massive amounts of IL-17 in 
response to IL-23. Once γδT-cells begin disappearing from CNS, 
CD4+ Tregs continue progressively infiltrating CNS and they 
recover their suppressive activity, which correlates with progres-
sive attenuation of EAE manifestation (18). In addition, there is 
a number of studies pointing to the participation of a regulatory 
subpopulation of CD8+ T-cells which dampen EAE severity 
(19, 20). In this regard, distinct subpopulations of CD8+ Tregs 
have been described, including CD8+CD122+, CD8+CD28−, and 
CD8+LAP+ (21–23). Altogether these findings strongly suggest 
that DCs, by regulating the activation and differentiation of 
both CD4+ and CD8+ T-cells, play a fundamental and complex 
role in the development of T-cell response involved in EAE. 
Regarding the pro-inflammatory function of antigen-presenting 
cells (APCs) in human, peripheral blood monocytes have 
been shown to represent an important source of inflammatory 
cytokines, including IL-12 and IL-23 (24, 25). Furthermore, it 
has been shown that the production of inflammatory cytokines 
is exacerbated in peripheral blood monocytes obtained from MS 
patients (25). Thus, these findings suggest that, in addition to 
DCs, human peripheral blood monocytes may also play a relevant 
immunomodulatory role as APCs in the physiopathology of MS.
Among five dopamine receptors (DRs) described so far, D1-
like DRs [including dopamine receptor D1 (DRD1) and DRD5] 
as well as D2-like DRs (including DRD2, DRD3, and DRD4) 
have been found in immune cells (26, 27). Emerging evidence 
suggests a relevant role for the dopaminergic regulation in the 
control of MS and EAE development (27–31). During EAE onset 
and at the peak of disease manifestations, there is an important 
increase of dopamine levels in the striatum (32). In addition, a 
reduced expression of DRD5 has been described in peripheral 
blood mononuclear cells (PBMCs) obtained from untreated MS 
patients when compared with PBMCs obtained from healthy 
donors (33). Furthermore, when patients were treated with IFN-β, 
a cytokine that attenuated disease manifestation, a progressive 
Abbreviations: Ab, antibody; BM, bone marrow; CNS, central nervous system; 
CFA, complete Freund’s adjuvant; Cl-Mo, classical monocytes; DCs, dendritic 
cells; DR, dopamine receptor; DRD5, DR D5; DRD5KO, DRD5-knockout; EDSS, 
expanded disability status score; EAE, experimental autoimmune encephalomy-
elitis; GFP, green fluorescent protein; GM-CSF, granulocyte-macrophage colony-
stimulating factor; HS, healthy subjects; HLA-DR, human leucocyte antigen DR; 
HRP, horseradish peroxidase; IFN-n, interferon n; IL-n, interleukin n; Int-Mo, 
intermediate monocytes; LAP, leucocyte alkaline phosphatase; LPS, lipopolysac-
charide; mAb, monoclonal antibody; MFI, mean fluorescence intensity; MOG, 
myelin oligodendrocyte glycoprotein; mDCs, myeloid DCs; NCl-Mo, non-
classical monocytes; NF-κB, nuclear factor kappa B; PRRs, pattern-recognition 
receptors; pMOG, peptide MOG; PBMC, peripheral blood mononuclear cells; 
BDCs, peripheral blood DCs; pDCs, plasmacytoid DCs; PE, phycoerythrin; 
PMA, phorbol 12-myristate 13-acetate; pSTAT3, phosphorylated STAT3; RORγt, 
RAR-related orphan receptor gamma; RSP, reserpine; SCH, SCH23390; STAT3, 
signal transducer and activator of transcription 3; STAT3ca, constitutively active 
STAT3; Tregs, regulatory T-cells; Thn, T helper n; TLRs, toll-like receptors; 
WT, wild type.
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increase on DRD5 expression was observed in PBMCs during 
the treatment period (34). Further studies analysing DRs in dif-
ferent T-cell subsets revealed an opposite deregulation of DRD5 
expression in Tregs and Teffs obtained from MS patients (35). 
Importantly, these studies strongly suggest the involvement of 
DRD5-signalling in immune cells in the physiopathology of MS.
Of note, previous findings have demonstrated that DCs, from 
human or mouse origin, express the whole machinery to synthe-
sise and store dopamine, which can be released upon maturation 
or antigen presentation (36, 37). Moreover, in vitro analyses have 
indicated that DRD5-stimulation in DCs favours the production 
of IL-12 and IL-23 by DCs (37). Since IL-12 and IL-23 can stimu-
late, respectively, Th1 and Th17 differentiation and also promote 
γδT-cell function (18) and generation of GM-CSF-producing 
CD4+ T-cells (14), all of them representing cell subpopulations 
involved in EAE pathogenesis, it is likely that DRD5-signalling 
in DCs plays a relevant role in EAE.
In this study, we aimed to unravel the relevance of DRD5-
signalling in DCs in the development of EAE and the underlying 
mechanism involved in the induction of an autoreactive T-cell 
mediated response. Moreover, we also studied the association 
of DRD5-signalling in APCs with MS. Our findings show here 
that DRD5-signalling confined to DCs promotes selectively 
the participation of inflammatory T-cell subsets in the CNS of 
EAE mice, including Th1, Th17, and GM-CSF-producing CD4+ 
T-cells, without affecting suppressive T-cells. Mechanistic analy-
ses demonstrated that DRD5-signalling was triggered by an auto-
crine loop exerted by dopamine derived from DCs. Furthermore, 
our results indicate that DRD5-signalling in DCs was mediated 
through the attenuation of STAT3-activation. Finally, our data 
obtained from human individuals indicates that DRD5–STAT3 
axis is also present in human monocytes and this signalling is 
upregulated in MS patients.
MaTerials anD MeThODs
animals
Six- to eight-week-old mice of the C57BL/6 background were 
used for all experiments. Wild-type (WT) C57BL/6 mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME, USA). 
DRD5-knockout (DRD5KO) mice were kindly donated by Dr. 
David Sibley (38), which were backcrossed for at least 10-genera-
tions in the C57BL/6 genetic background. CD11c.DOG mice in 
the C57BL/6 genetic background were kindly donated by Dr. 
Natalio Garbi and Günter Hämmerling (39). All mice were main-
tained and manipulated according to institutional guidelines at 
the pathogen-free facility of the Fundación Ciencia & Vida.
reagents
PerCP–anti-CD4 (GK1.5), PerCP–anti CD8 (53-6.7), allophyco-
cyanin–anti-IFN-g (XMG1.2), phycoerythrin (PE)-Cy7–anti-IL-
17A (TC11-18H10.1), PE–anti-GM-CSF (MP1-22E9), Brilliant 
Violet 421–anti-TCRγδ (GL3), Brilliant Violet 421–anti-leucocyte 
alkaline phosphatase (LAP) (TW7-16B4), PE–anti-CD122 (5H4), 
allophycocyanin–anti CD28 (E18) Abs, and Cell Trace Violet 
were purchased from BioLegend. Allophycocyanin–anti-Foxp3 
(FJK16s) antibody (Ab) was obtained from eBioscience. Anti-
phospho-STAT3 (3E2) and anti-STAT3 (79D7) were obtained 
from Cell Signaling. Phorbol 12-myristate 13-acetate (PMA) and 
ionomycin were purchased from Sigma-Aldrich. Horseradish 
peroxidase (HRP)–anti-rabbit IgG Ab was obtained from Santa 
Cruz Biotechnology. HRP-conjugated anti-mouse IgG Ab was 
purchased from Rockland Immunochemicals. Brefeldin A 
was obtained from Life Technologies. The pMOG (MOG35–55) 
was purchased from GeneTel Laboratories (Madison, WI, USA).
generation of Mouse Dcs
Bone marrow-derived DCs (BM-DCs) from WT and DRD5KO 
mice were prepared as previously described (37). Briefly, DCs 
were grown in RPMI 1640 medium (Hyclone, Logan, UT, 
USA) supplemented with 10% heat-inactivated FBS (Biological 
Industries, Beit Haemek, Israel) and 10  ng/ml recombinant 
mouse GM-CSF (PeproTech, Rocky Hill, NJ, USA). On day 5, 
differentiation of DCs was routinely assessed obtaining <80% 
CD11c+ cells. In some experiments, day 5 DCs were either left 
unstimulated or stimulated with 100  ng/ml lipopolysaccharide 
(LPS) (Sigma Chemical Co., St. Louis, MO, USA) for 24 h and 
used for further experiments.
intracellular cytokine staining analysis
To analyse cytokine production, cells were restimulated with 
1 mg/ml ionomycin and 50 ng/ml PMA for 4 h in the presence 
of 5 mg/ml brefeldin A. For intracellular staining, cells were first 
stained with a Zombie Aqua fixable viability kit (BioLegend), fol-
lowed by staining for cell surface markers. Intracellular staining 
was done with the Foxp3 staining buffer set (eBioscience). Data 
were collected with a FACSCanto (BD Biosciences) and analysed 
with FlowJo software (Tree Star).
Western Blot
To analyse the phosphorylation of STAT3, 2 × 106 cells/ml DCs 
were cultured in the presence or the absence of 100 ng/ml LPS 
and either left untreated or treated with 1 µM SCH23390 (SCH) 
or 1  µM reserpine (RSP; Tocris, Bristol, UK) for 8  h. Samples 
containing 50 µg protein were run on denaturing conditions and 
transferred to polyvinylidene difluoride membranes (Thermo 
Scientific). Phosphorylated STAT3 (pSTAT3) was detected with a 
mouse monoclonal antibody and HRP-conjugated secondary Ab 
against mouse IgG. STAT3 expression was detected using a rabbit 
polyclonal Ab and HRP-conjugated secondary Ab against rabbit 
IgG. Immunodetection was carried out using SuperSignal West 
Femto chemiluminescent substrate (Thermo Scientific).
lentiviral Transduction
Constitutively active STAT3 (STAT3ca, Cys substitutions at 
Ala662 and Asn664) cDNA were cloned in pLNCX vector and 
kindly provided by Dr. Robert Arceci (40). For the construction 
of the lentiviral vector codifying STAT3ca, mouse STAT3ca 
sequence was excised from pLNCX vector and subcloned into a 
pLVX-IRES-ZsGreen1 vector (Clonetech). Recombinant lentivi-
ruses were produced by transfecting HEK293T with the lentiviral 
expression plasmid pLVX-IRES-ZsGreen1 or pLVX-STAT3ca and 
the packaging plasmids pCMV-dR8.91 and pCMV-VSV-G using 
TaBle 1 | Characteristics of the subjects included in the study.
healthy 
subjects
Multiple sclerosis 
patients
p
n (F/M) 10 (7/3) 9 (5/4) 0.650
Age (years) 42.3 ± 8.4 46.4 ± 9.5 0.326
Disease duration (years) 19.4 ± 9.3
Baseline expanded disability 
status score (median ± SD)
2.9 ± 2.1
Treatmentsa
Interferon (IFN)-β1a
 – Avonex®, Biogen 2
 – Plegridy®, Biogen 2
 – Rebif44®, Serono 1
iFn-β1b
 – Extavia®, Novartis 3
 – Betaferon®, Bayer 1
Values are mean ± SD unless otherwise indicated.
aAccording to the approved therapeutic regimens.
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Turbofect (Termofisher) according manufacturer instructions. 
Infectious lentiviruses were harvested at 48 h post-transfection 
and then concentrated. The infectious titre was determined by 
FACS by quantifying expression of green fluorescent protein 
(GFP) in infected HEK293T  cells. DCs were transduced with 
STAT3ca or control lentivirus on days 4 and 5 of differentiation 
at MOI 10 in the presence of 2 µg/ml polybrene.
eae induction and evaluation
Experimental autoimmune encephalomyelitis induction and 
the transfer of DCs were carried out as described before (41). 
Briefly, 6- to 8-week-old female WT, DRD5KO, or CD11c.DOG 
mice were injected s.c. with 50 mg pMOG (Genetel Laboratories, 
Madison, WI, USA) emulsified in complete Freund’s adjuvant 
(CFA) (Invitrogen) supplemented with heat-inactivated 
Mycobacterium tuberculosis H37 RA (Difco Laboratories, 
Detroit, MI, USA). In addition, mice received i.p. injections 
of 500 ng pertussis toxin (Calbiochem, La Jolla, CA, USA) on 
days 0 and 2. Clinical signs were assessed daily according to the 
following scoring criteria: 0, no detectable signs; 1, flaccid tail; 
2, hind limb weakness or abnormal gait; 3, complete hind limb 
paralysis; 4, paralysis of fore and hind limbs; and 5, moribund 
or death. In some EAE experiments, 106 BM-DCs from WT and 
DRD5KO mice were pulsed with 5 mg/ml pMOG for 4 h and 
then i.v. transference were done into WT C57BL/6 recipient 
mice 14 and 7 days before EAE induction. In experiments using 
CD11c.DOG mice as recipients, animals were daily injected with 
Diphteria Toxin (8 μg/Kg) to eliminate endogenous DCs (39) 
from day 9 to day 5 before EAE induction. These mice received 
the i.v. transference of pMOG-pulsed WT or DRD5KO DCs 
on day 7 before EAE induction. For the preparation of CNS 
mononuclear cells, mice were transcardially perfused with cold 
PBS. The brain and spinal cord were dissected, and CNS tissue 
was cut into small pieces and digested by collagenase D (2.5 mg/
ml; Roche Diagnostics) and DNaseI (1 mg/ml; Sigma) at 37°C 
for 45  min. Digested tissue was passed through a 70-mm cell 
strainer obtaining single cell suspension that was subjected to 
centrifugation in a Percoll gradient (70/40%). Mononuclear cells 
were removed from the interphase and resuspended in culture 
medium for further analysis.
evaluation of caMP and Dopamine
Dendritic cells were harvested, washed, and resuspended in 
RPMI 1640 medium at 106 cells/ml. cAMP was determined 
as described (42). Briefly, cells were incubated with 50  nM of 
Zardaverine (Tocris) for 30 min at 37°C and then treated with 
or without dopamine (Sigma) at indicated concentrations in the 
presence or absence of 500 nM Forskolin (Tocris). After incubat-
ing for 45 min at 37°C, cells were lysed and cAMP concentration 
was determined using cAMP-Screen Direct System (Applied 
Biosystems) according to the manufacturer’s instructions. To 
determine the levels of dopamine released into the culture super-
natant, DCs were treated with the indicated stimuli at 37°C for 
60 min and then the supernatant was separated by centrifugation. 
Dopamine levels were quantified in the supernatant by using an 
ELISA-based kit (Alpco Diagnostics) following the manufactur-
ers recommendations.
human subjects
Patients with relapsing/remitting MS according to the revised 
McDonald’s criteria (43) treated with IFN treatment according 
to the Italian Ministry of Health’s guidelines were included in the 
study (see Table 1). Patients were enrolled at the MS Center of the 
Hospital S. Antonio Abate, Gallarate (VA, Italy). Healthy subjects 
(HS) were usually spouses and caregivers of enrolled MS patients. 
Subjects with neuropsychiatric disorders (e.g., depression) were 
excluded from the study. At the time of enrolment, all patients 
were free from relapse since at least 1 month, no one was receiving 
sympathoadrenergic agents, dopaminergic agents, or antidepres-
sants at least during the prior 3  months nor steroid treatment 
in the last month. Functional disability was measured using the 
Kurtzke expanded disability status score (44).
Venous blood samples were obtained after a fasting night, 
between 8:00 a.m. and 10:00 a.m., in universal tubes containing 
10.7 mg ethylenediaminetetraacetic acid dipotassium salt. Tubes 
were subsequently coded and stored at room temperature (RT) 
until processing, which occurred within 2 h after collection.
Flow cytometric analysis of human Dcs 
and Monocytes and of Drs expression
Analysis of DRs on DCs and monocytes was performed accord-
ing to a previously established method (45) with modifications. 
Briefly, 200 μl aliquots of whole blood were prepared and eryth-
rocytes were removed by means of a lysis buffer [composition 
(g/l in ultrapure water): NH4Cl 8.248, KHCO3 1.0, EDTA 0.0368]. 
Incubation was performed at RT for 5 min, during which samples 
were gently vortexed. Samples were then centrifuged at 600 g for 
5 min at RT, supernatants were removed, and cells were washed 
one time in 1 ml of PBS [composition (g/l in ultrapure water): NaCl 
8.4, Na2HPO4 1.424, NaH2PO4 0.276] at pH 7.4 supplemented 
with 1% BSA (Sigma, Italy) (PBS/BSA), once more centrifuged at 
600 g for 5 min at RT, and finally resuspended in 100 µl PBS/BSA. 
From each subject, 13 aliquots of whole blood were prepared and 
processed for evaluation of DCs (6 aliquots: 5 for DRs staining, 1 
as control for the secondary Ab) and of monocytes (7 aliquots: 5 
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for DRs staining, 1 as control for the secondary Ab, and 1 for the 
anti-CD16 Ab isotype control).
The staining protocol consisted of two steps. During the first 
step, each aliquot was treated with 5  µl Fc block solution for 
10 min at RT to prevent any unwanted binding of anti-human 
Ab to Fc receptors and thereafter stained for one of the five DRs 
by an indirect labelling procedure (primary Ab + secondary Ab). 
Aliquots were incubated with the primary anti-DR Ab for 30 min 
on ice in the dark, washed one time with PBS/BSA at 600 g for 
5  min at RT, and resuspended in 100  µl PBS/BSA containing 
the secondary Ab and incubated for 30 min on ice in the dark. 
Aliquots were then washed (600  g for 5  min at RT) and once 
more resuspended in 100 µl PBS/BSA. During the second step, 
the aliquots for evaluation of DCs were incubated with a cocktail 
of anti-human Lin1, human leucocyte antigen DR (HLA-DR), 
CD123, and CD11c, for the identification of total circulating 
DCs (Lin1-/HLA-DR+), plasmacytoid DCs (pDCs, CD123high/
CD11c−), and myeloid DC (mDC, CD123low/CD11chigh), whilst 
the aliquots for evaluation of monocytes were incubated with a 
cocktail of anti-human CD45, HLA-DR, CD14, and CD16 for 
the identification of classical (CD14high/CD16−), non-classical 
(CD14low/CD16high), and intermediate (CD14high/CD16+) mono-
cytes. As a control of isotype, cells were stained with an IgG1k 
of irrelevant specificity instead of the anti-human CD16 Ab. All 
aliquots were incubated for 20 min in dark at RT, washed with 
1 ml of PBS/BSA (600 g for 5 min at RT), finally resuspended 
in 600 µl PBS and kept on ice until analysis. The complete list of 
Ab used in the protocols together with their working dilutions is 
shown in Table S1 in Supplementary Material.
Acquisition and analysis were performed on a BD FACSCanto 
II flow cytometer (Becton Dickinson, Milan, Italy) with BD 
FACSDiva software (version 6.1.3). The gating strategies used to 
identify DCs and monocytes are shown in Figures S9 and S10 
in Supplementary Material, respectively. The results were finally 
expressed as absolute numbers (103/mm3) as well as percentage 
of positive cells (%), as well as mean fluorescence intensity (MFI) 
of positive cells, calculated as the difference between MFI in 
anti-human DR Ab stained aliquots and aliquots stained with the 
secondary Ab alone.
Flow cytometric assay of psTaT3 in 
human Monocytes
Samples of 200 µl whole blood from HS were kept for 5 min on ice 
in the dark, alone or in the presence of different concentrations of 
dopamine hydrochloride (Sigma, Italy; code H8502). Thereafter, 
samples were added with anti-human CD14 Ab and incubated for 
20 min at 37°C in a water bath. During this period, 100 ng/ml IL-6 
(Biolegend, San Diego, CA, USA; code 570804) was eventually 
added after 5 min.
Erythrocyte lysis and cell fixation and permeabilisation for 
intracellular staining of pSTAT3 were then performed according 
to BD Phosflow Protocol III for Human Whole Blood (http://
www.bdbiosciences.com/us/applications/research/intracellular-
flow/m/745716/resources). Briefly, samples were added with 3 ml 
of pre-warmed Lys/Fix Buffer 1X and incubated for 12  min at 
37°C in a water bath. Samples were then centrifuged at 600 g for 
7 min at RT, supernatants were removed and cells were washed 
with 3 ml of Dulbecco’s PBS 1X [composition (g/l in ultrapure 
water): CaCl2 0.1, MgCl2·6 H2O 0.1, KCl 0.2, KH2PO4 0.2, NaCl 
8.0, Na2HPO4·7 H2O 2.16] at pH 7.4. After another centrifuga-
tion (600 g for 7 min) supernatants were removed and cells were 
added with 1 ml of pre-chilled Perm Buffer III and incubated for 
30 min on ice. Cells were then washed twice in 3 ml of Stain Buffer 
(600 g for 7 min each). Supernatants were thereafter removed, 
cells were resuspended in 100 µl of Stain Buffer and added with 
anti-human pSTAT3 ab. Samples were subsequently incubated 
for 30 min in the dark at RT, washed with 3 ml of stain buffer 
(600 g for 7 min), finally resuspended in 500 µl stain buffer and 
kept on ice until analysis. The complete list of Ab used in the 
protocol together with their working dilutions is shown in Table 
S1 in Supplementary Material.
Acquisition and analysis were performed on a BD FACSCanto 
II flow cytometer (Becton Dickinson, Milan, Italy) with BD 
FACSDiva software (version 6.1.3). The gating strategies used 
to identify pSTAT3+ monocytes are shown in Figure S7 in 
Supplementary Material. The results were finally expressed as 
percentage of positive cells (%), as well as MFI of positive cells, 
calculated as the difference between MFI in anti-human DR Ab 
stained aliquots and aliquots stained with the secondary Ab alone.
statistical analysis
All values were expressed as mean ± SEM. Differences in means 
between two groups were analysed by two-tailed Student’s t-test. 
Progression of EAE severity curves were compared with a non-
parametric Mann–Whitney rank sums two-tailed U-test. P value 
≤0.05 was considered significant. Analyses were performed with 
GraphPad Prism 6 software.
study approval
The study performed with human individuals conforms to the 
principles outlined in the Declaration of Helsinki, the study 
protocol was approved by the local Ethics Committee of the 
Ospedale di Circolo and Fondazione Macchi, Varese (Italy), and 
all the participants signed a written informed consent before 
enrolment. All procedures performed in animals were approved 
by and complied with regulations of the Institutional Animal 
Care and Use Committee at Fundación Ciencia & Vida.
resUlTs
DrD5-signalling in Dcs Favours the 
Development of aggressive eae
To determine whether DRD5 expressed in DCs was functional, we 
first tested the signalling pathway coupled to this receptor. Similar 
to most reports analysing the coupling of DRD5 in different cell 
types (46), our results show here that DRD5-stimulation in DCs 
was coupled with cAMP production (Figure S1 in Supplementary 
Material). To evaluate the role of DRD5-signalling confined to DCs 
in the development of EAE, we first performed a set of adoptive 
transfer experiments in which WT or DRD5KO DCs were loaded 
ex vivo with the autoantigen associated with EAE, a peptide derived 
from MOG (pMOG), and then transferred into WT recipients in 
which EAE was induced. The results show that DRD5-deficiency 
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in DCs results in a significant attenuation in the severity of EAE 
manifestation during the peak of the disease manifestation and 
also during the recovery phase (Figure  1A). The experimental 
settings used in these experiments open the possibility that a frac-
tion of pMOG-loaded DRD5KO DCs transferred were dying and 
phagocytosed by endogenous WT DCs, thus dampening the final 
effect of DRD5-deficiency in EAE. To rule out this possibility, we 
performed similar experiments but transferring pMOG-loaded 
DCs into WT recipients previously depleted of endogenous DCs. 
For this purpose, we used CD11c.DOG mice as recipients, which 
express the diphtheria toxin (DT) receptor under the control of 
CD11c-promoter (39). We depleted endogenous DCs in CD11c.
DOG mice with DT during the time frame in which pMOG-loaded 
WT or DRD5KO DCs were transferred and then EAE development 
was analysed. These results show that lack of DRD5-signalling in 
pMOG-loaded DCs transferred into DCs-depleted recipient mice 
results in a significant reduction of EAE manifestation (Figure S2 
in Supplementary Material). The reduction in EAE severity due to 
DRD5-deficiency in DCs was similar when endogenous DCs were 
depleted or not (Figure 1A; Figure S2 in Supplementary Material), 
thereby indicating that endogenous DCs did not interfere with 
the priming of pMOG-response induced by transferred pMOG-
loaded ex vivo DCs.
DrD5-Deficiency confined to Dcs results 
in reduced Frequencies of inflammatory 
cD4+ T-cells in the cns of eae Mice
In a previous study, we observed that DRD5-signalling in DCs was 
required to induce high frequencies of Th17 cells infiltrating the 
CNS during the peak of disease manifestation in EAE mice (37). 
To gain a wide and deeper insight in the mechanism involved in 
the pro-inflammatory effect of DRD5-signalling in DCs favour-
ing the development of EAE, in this study, we analysed how it 
was affecting a broad panel of inflammatory and suppressive 
subsets of T-cell infiltrating the CNS during the peak of disease 
manifestation and during the recovery phase of EAE. For this 
purpose, we analysed the relative frequencies not only of Th1 and 
Th17 cells but also double positive IFN-γ+ IL-17+, and the highly 
inflammatory GM-CSF+ subsets including IFN-γ+ GM-CSF+, 
IL-17+ GM-CSF+, and IFN-γ+ IL-17+ GM-CSF+ CD4+ T-cells 
(14). The results show that despite DRD5-deficiency in DCs 
affected only Th17, IFN-γ+ IL-17+, and IFN-γ+ IL-17+ GM-CSF+ 
subsets of CD4+ T-cells during the peak of disease manifestation, 
Th1 and the highly inflammatory GM-CSF+ CD4+ T-cells were 
also significantly reduced in the CNS during the recovery phase 
of EAE (Figures 1B,C; Figure S3 in Supplementary Material). In 
addition, we evaluated the frequency of γδT-cells, which have 
been described to produce IL-17 and to inhibit the suppressive 
activity of Tregs in the CNS during the peak of EAE manifestation 
(18). However, we did not find differences in the extent of total 
γδT-cells or IL-17-producers γδT-cells in the CNS of EAE mice 
receiving WT versus DRD5KO DCs (Figure S4 in Supplementary 
Material). Moreover, we analysed whether DRD5-signalling in 
DCs was affecting the participation of T-cell subsets with sup-
pressive activity in EAE, including Foxp3+ CD4+ Tregs, as well 
as LAP+, CD122+, and CD28− CD8+ T-cells (21–23). We found 
no differences in the frequency of any of these suppressive T-cell 
subsets during the recovery phase and only a reduced frequency 
in Foxp3+ CD4+ Tregs infiltrating the CNS during the peak of the 
disease manifestation when mice lack DRD5-signalling in DCs 
(Figure S5 in Supplementary Material). Nevertheless, this latter 
difference was irrelevant as the extent of γδT-cells, which inhibit 
the Tregs function during the peak of the disease (18), was not 
affected by DRD5-signalling in DCs (Figure S4 in Supplementary 
Material). Thereby, the overall effect of DRD5-signalling in DCs 
was to favour the participation of inflammatory CD4+ T-cell 
subsets in the CNS of EAE mice, especially in the recovery phase.
The Pro-inflammatory effect of DrD5-
signalling in Dcs is Mediated by the 
inhibition of sTaT3 Phosphorylation
We previously described that DRD5-signalling in DCs favours 
selectively the production of both IL-23 and IL-12 (37). Since 
STAT3 has been involved in the repression of both of these 
cytokines in DCs (10, 11), we next evaluated whether DRD5-
signalling in DCs involves the regulation of STAT3 activation. For 
this purpose, we induced STAT3 activation in DCs by stimula-
tion with LPS (10) and then we analysed how DRD5-deficiency 
affected the extent of STAT3-phosphorylation by Western blot. 
These results show that lack of DRD5-signalling in DCs results 
in an exacerbated phosphorylation of STAT3 induced by LPS 
(Figure 2A), indicating that DRD5-signalling attenuates STAT3 
activation in these cells. To determine the relevance of STAT3 
activation in DCs in the development of EAE, we next transduced 
WT DCs with lentiviral vectors codifying for an STAT3ca (40) and 
GFP as reporter gene or with control vectors codifying only for 
GFP. Transduced cells were purified by cell sorting based on GFP-
expression and then loaded ex vivo with pMOG and transferred 
into WT recipients in which EAE was induced. When STAT3ca-
transduced DCs were transferred in a prophylactic regime to EAE 
mice, there was a significant attenuation of EAE manifestation in 
comparison with those animals receiving uninfected DCs or DCs 
transduced with control vectors (Figure 2B). Furthermore, when 
STAT3ca-transduced DCs were administered to EAE mice in a 
therapeutic context (day 10 post-induction), the disease severity 
was also strongly reduced (Figure 2C). To confirm the relevance 
of DRD5–STAT3 axis in DCs in favouring the development of 
EAE using a pharmacologic approach, we next performed a set 
of experiments using the D1-like-selective antagonist SCH23390. 
According to the genetic evidence indicating the role of DRD5-
signalling in the inhibition of STAT3 activation (Figure 2A), when 
LPS-stimulated DCs were pre-incubated with SCH23390, an 
exacerbated STAT3-phosphorylation was observed (Figure 3A, 
top panel). Furthermore, when pMOG-loaded DCs were ex vivo 
treated with SCH23390 and then transferred into EAE mice in 
a prophylactic regime, we observed a decrease in disease sever-
ity (Figure  3C) in a similar extent of that reduction observed 
when DRD5KO DCs (Figure 1A) or STAT3ca-transduced DCs 
(Figure 2B) were transferred into EAE mice. Nevertheless, when 
pMOG-loaded SCH23390-treated DCs were transferred into 
EAE mice in a therapeutic context, there was no effect in disease 
severity (Figure 3D). Taken together, these results indicate that 
DRD5–STAT3 axis in DCs promotes the inflammatory response 
involved in EAE development.
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FigUre 1 | Continued
FigUre 2 | DRD5-signalling in dendritic cells (DCs) involves attenuation of signal transducer and activator of transcription 3 (STAT3) phosphorylation and the 
transduction of DCs with a constitutively active version of STAT3 exerts a therapeutic effect in experimental autoimmune encephalomyelitis (EAE). (a) Wild type (WT) 
or DRD5-knockout (DRD5KO) bone marrow-derived DCs (BM-DCs) were left unstimulated or treated with lipopolysaccharide (LPS) (250 ng/ml) for 8 h. Cells were 
lysed in the presence of phosphatase inhibitors, and the presence of phosphorylated STAT3 (pSTAT3, top panel) or total STAT3 irrespective of phosphorylations 
(STAT3, bottom panel) were analysed in protein extracts by Western blot. Representative data from one out of three independent experiments is shown. Not edited 
blots are shown in Figure S13 in Supplementary Material. (B,c) WT BM-DCs were left uninfected (black symbols), transduced with an empty lentiviral vector (pLVX, 
open symbols) or transduced with a lentiviral vector expressing a constitutively active form of STAT3 (STAT3ca, grey symbols) and pulsed with pMOG. DCs were 
transferred (106 DCs/mice; i.v. injections) into WT recipient mice at days 14 and 7 prior to EAE induction (B) or 10 days post-induction (c). The time of the 
therapeutic treatment in panel (c) is indicated by an arrow. Disease severity was evaluated as clinical score (see Materials and Methods) from day 0 to day 25 
post-induction. Data from six to eight mice per group, corresponding to a representative from three independent experiments, are shown. Values represent 
mean ± SEM. **p < 0.01; ***p < 0.001; by Mann–Whitney U-test in the indicated time frames. Significant differences between uninfected and treated with pLVX are 
indicated in black brackets while differences between infected with pLVX and infected with STAT3ca are indicated in grey brackets.
FigUre 1 | Lack of DRD5-signalling in dendritic cells (DCs) results in a reduction in the frequencies of Th1, Th17, GM-CSF+, and interferon (IFN)-γ+ IL17+ CD4+ 
T-cells infiltrating the central nervous system of experimental autoimmune encephalomyelitis (EAE) mice. Wild type (WT) (black lines) or DRD5-knockout (DRD5KO) 
(grey line) bone marrow-derived DCs were pulsed with pMOG and transferred (106 DCs/mice; i.v. injections) into WT recipient mice at days 14 and 7 prior EAE 
induction. (a) Disease severity was evaluated as clinical score (see Materials and Methods) from day 0 to day 25 post-induction. Data from at least 14 mice per 
group are shown, corresponding to a representative from three independent experiments. Values represent mean ± SEM. *p < 0.05; ***p < 0.001 by Mann–Whitney 
U-test in the indicated time frames. (B,c) At the peak (17–19 dpi) or at the recovery phase (25 dpi) of the disease, mononuclear cells were isolated from central 
nervous system (CNS) followed by ex vivo stimulation with phorbol 12-myristate 13-acetate/ionomycin in the presence of brefeldin A, and intracellular cytokine 
staining analysis was carried out by flow cytometry. Inflammatory populations were analysed at the peak (left panels) or at the recovery phase (right panels). (B) 
Representative dot-plots for interleukin (IL)-17, IFN-γ, and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in the infiltrating CD4+ gated 
population are shown. Numbers on the dot-plots indicate the percentage of cells in the associated region. (c) Frequencies of inflammatory T-cells infiltrating the 
CNS are represented as the mean ± SEM. *p < 0.05 by unpaired two-tailed Student’s t-test.
8
Prado et al. Dopaminergic Signalling Favours Autoimmunity
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 571
The Dopamine Produced by Dcs 
constitutes a relevant source to Trigger 
DrD5-signalling
Previous studies have shown that DCs from mouse and human 
origin may produce and store dopamine in intracellular vesicles 
(36, 37). Moreover, in  vitro analyses have suggested that toll-
like receptor-stimulation and antigen-presentation are stimuli 
to induce dopamine release from DCs (36, 37). Thus, we next 
addressed the question of whether the dopamine produced 
by DCs is a relevant source for the autocrine stimulation of 
DRD5-signalling in vivo in the context of EAE. Accordingly, we 
performed a set of experiments using RSP, a drug that reverts 
the flow of the vesicular monoamine transporter, promoting the 
depletion of dopamine from secretory vesicles and redirecting it 
to the secretion to the extracellular compartment or degradation 
in the cytoplasm by the action of oxidative enzymes (29). Notably, 
when dopamine was depleted from DCs prior to LPS stimula-
tion (Figure  3B), an exacerbated STAT3-phosphorylation was 
observed (Figure 3A, bottom panel), suggesting that dopamine 
contained inside DCs was required to DRD5-mediated inhibition 
of LPS-induced STAT3 activation. As expected, we observed that 
the treatment of DCs with RSP induced dopamine release into 
the culture supernatant (Figure 3B). To confirm the relevance of 
DCs as a source of dopamine to self-stimulate DRD5-signalling 
in vivo, we treated WT DCs with RSP ex vivo, which were then 
loaded with pMOG and transferred into EAE mice. Importantly, 
the results show that dopamine-depletion in DCs results in 
a significant reduction of EAE manifestation when pMOG-
loaded DCs were administered in both contexts prophylactic or 
therapeutic (Figures 3C,D). Therefore, these results indicate that 
dopamine produced by DCs constitutes a relevant source of this 
mediator, which exerts an autocrine loop for the stimulation of 
DRD5-signalling in vivo.
Dopamine attenuates sTaT3 
Phosphorylation in human Monocytes
In the above experiments, we used BM-DCs as a source of APCs, 
which have been described to be constituted by a heterogeneous 
FigUre 3 | Pharmacologic inhibition of D5R-signalling or the depletion of dopamine on dendritic cells (DCs) reduces the severity of experimental autoimmune 
encephalomyelitis (EAE). (a) Wild type (WT) bone marrow-derived DCs (BM-DCs) were left untreated (UT) or treated with either the DRD1/DRD5 antagonist 
SCH23390 (SCH) or reserpine (RSP), alone or in the presence of lipopolysaccharide (LPS) (250 ng/ml) for 8 h. Cells were lysed in the presence of phosphatase 
inhibitors, and the presence of phosphorylated STAT3 (pSTAT3, top panel) or total signal transducer and activator of transcription 3 (STAT3) irrespective of 
phosphorylations (STAT3, bottom panel) was analysed in protein extracts by Western blot. Representative data from one out of three independent experiments are 
shown. Not edited blots are shown in Figure S13 in Supplementary Material. (B) WT DCs were either left unstimulated (control) or stimulated with 1 µM RSP for 
60 min and then dopamine release was determined in the supernatant by an ELISA-based kit. A representative result from two independent experiments is shown. 
(c,D) WT BM-DCs were left untreated (black symbols), treated with SCH23390 1 µM (open symbols) or treated with RSP 1 µM (grey symbols) as described and 
pulsed with pMOG. DCs were transferred (106 DCs/mice; i.v. injections) into WT recipient mice at days 14 and 7 prior to EAE induction (c) or 10 days post-induction 
(D). The time of the therapeutic treatment in (D) is indicated by an arrow. Disease severity was evaluated as clinical score (see Materials and Methods) from day 0 to 
day 25 post-induction. Data from six to eight mice per group, corresponding to a representative from three independent experiments, are shown. Values represent 
mean ± SEM. *p < 0.05 by Mann–Whitney U-test in the indicated time frames. Significant differences between untreated and treated with SCH23390 are indicated 
in black brackets while differences between untreated and treated with reserpine (RSP) are indicated in grey brackets.
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mixture of myeloid APCs, including DCs, monocytes/mac-
rophages, and cells expressing phenotypic markers of both DCs 
and monocytes/macrophages (47). In human, whereas mono-
cytes constitute about 7–9% of PBMCs, DCs represent less than 
1% (see Table 2). Since blood samples obtained were of a very 
limited volume, monocytes are significantly more abundant than 
DCs in human blood and they constitute a substantial fraction 
of APCs present in mouse BM-DCs (see CD14+ population in 
Figure S6 in Supplementary Material), we next evaluated whether 
STAT3 activation was also inhibited by dopaminergic stimulation 
in human monocytes. Accordingly, blood cells obtained from 
healthy controls were treated with IL-6, a stimulus previously 
described to induce STAT3 activation (48), and the extent of 
STAT3 phosphorylation was evaluated by flow cytometry in the 
CD14+ population using the gating strategy indicated (Figure S7 
in Supplementary Material). Importantly, when monocytes were 
pre-incubated with increasing concentrations of dopamine, only 
1 µM dopamine but not lower concentrations of dopamine, was 
able to reduce significantly the extent of STAT3-phosphorylation 
induced by IL-6 (Figure 4). Similar results were obtained when 
mouse BM-DCs were stimulated with IL-6 in the presence of 
1  µM dopamine (Figure S8 in Supplementary Material). Thus, 
TaBle 2 | Complete blood count.
Units range hsa Ms patientsa p
RBC 1012/L 4.5–6.0 4.6 ± 0.4 4.8 ± 0.4 0.400
Haemoglobin g/dL 13.0–17.5 13.8 ± 1.2 14.3 ± 1.2 0.452
Platelets 109/L 150–450 254.3 ± 61.7 218.4 ± 15.2 0.158
WBC 109/L 4.3–11.0 6.0 ± 0.9 6.1 ± 2.0 0.860
Neutrophils 109/L 1.5–5.5 3.5 ± 0.7 3.8 ± 1.7 0.674
% 40–80 58.1 ± 5.1 60.4 ± 10.2 0.557
Lymphocytes 109/L 1.5–5.5 1.9 ± 0.3 1.7 ± 0.8 0.420
% 10–45 32.3 ± 5.1 28.0 ± 9.6 0.268
N/L 1.9 ± 0.4 2.5 ± 1.1 0.151
Monocytes 109/L 0.2–1.1 0.4 ± 0.1 0.5 ± 0.2 0.194
% 2–12 6.8 ± 1.6 8.9 ± 3.4 0.131
Monocyte subsets
Classical 109/L 0.31 ± 0.12 0.36 ± 0.14 0.495
% of monocytes 73.8 ± 18.0 70.8 ± 7.5 0.651
Intermediate 109/L 0.05 ± 0.01 0.09 ± 0.03 0.009
% of monocytes 13.2 ± 2.5 16.2 ± 5.2 0.136
Non-classical 109/L 0.03 ± 0.02 0.07 ± 0.04 0.023
% of monocytes 8.2 ± 2.6 13.5 ± 5.8 0.022
DC 109/L 0.017 ± 0.005 0.017 ± 0.007 0.864
% of PBMC 0.8 ± 0.2 0.8 ± 0.2 1.000
Dc subsets
pDC 109/L 0.005 ± 0.002 0.004 ± 0.001 0.262
% of DC 27.0 ± 10.3 26.0 ± 8.7 0.825
mDC 109/L 0.007 ± 0.001 0.008 ± 0.004 0.715
% of DC 45.3 ± 11.4 44.3 ± 12.8 0.873
Data are mean ± SD.
RBC, red blood cells; WBC, white blood cells; N/L, neutrophils-lymphocytes ratio; 
PBMC, peripheral blood mononuclear cells; HS, healthy subjects; MS, multiple 
sclerosis; mDC, myeloid DC; pDC, plasmacytoid DC.
aData are missing for one HS and two MS patients.
FigUre 4 | Signal transducer and activator of transcription 3 (STAT3) 
phosphorylation is decreased by dopamine in human monocytes. Fresh blood 
samples obtained from healthy donors were unstimulated or pre-incubated 
with dopamine (DA) in the presence or absence of interleukin (IL)-6 for 15 min. 
Afterwards, the extent of phosphorylated STAT3 (pSTAT3) was evaluated by 
intracellular immunostaining in the CD14+ population and analysed by flow 
cytometry using the gating strategy indicated in Figure S7 in Supplementary 
Material. (a) Representative histograms for pSTAT3 in peripheral blood CD14+ 
cells unstimulated (black lines) or treated with 1 µM DA (green lines) in the 
absence (left panel) or in the presence of IL-6 (right panel). The extent of 
pSTAT3 was also determined in peripheral blood CD14+ cells stimulated with 
IL-6 alone (red line). (B) The extent of pSTAT3 in unstimulated (white symbols) 
or IL-6 treated (black symbols) CD14+ in the presence of increasing DA 
concentrations was quantified as the mean fluorescence intensity (MFI) 
associated with pSTAT3-immunostaining (left panel) or as the ratio of the 
pSTAT3-associated MFI of stimulated cells to the pSTAT3-associated MFI of 
unstimulated cells (in-fold, right panel). Values represent mean ± SEM, n = 5. 
*p < 0.05 by unpaired two-tailed Student’s t-test.
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considering the affinities described for the binding of dopamine 
to the different DRs (27), these results suggest that the selective 
stimulation of DRD5-signalling in human monocytes is also 
coupled to the inhibition of STAT3 activation.
Ms Patients Display a selective 
Overexpression of Drs in Peripheral  
Blood inflammatory Monocytes
The results above indicate that DRD5–STAT3 axis in APCs pro-
motes the inflammatory response associated with EAE in mouse 
and suggest that DRD5–STAT3 axis in APCs is also present in 
human. According to this evidence, we next wanted to evaluate 
whether DRD5-signalling in APCs was altered in MS patients in 
comparison to HS. For this purpose, we analysed the expression 
of all five DRs in several APCs populations present in human 
peripheral blood, including different subsets of DCs and mono-
cytes. Whereas DCs subsets analysed included pDCs, mDCs, and 
total peripheral blood DCs (BDCs) (49), the analysis in mono-
cytes was dissected in classical monocytes (Cl-Mo, described to 
exert phagocytic and non-inflammatory function), non-classical 
monocytes (NCl-Mo, associated to inflammatory and APC 
function), and intermediate monocytes (Int-Mo, a transitional 
subset displaying phagocytic and inflammatory features) (50). 
DRs expression was analysed in all these APCs populations by 
flow cytometry using the gating strategy described in the supple-
mentary material for DCs (Figure S9 in Supplementary Material) 
and for monocytes (Figure S10 in Supplementary Material). The 
study enrolled 10 HS and 9 MS patients (Table 1). As shown in 
Table 2 and Figure S11 in Supplementary Material, the subsets 
of DCs analysed in HS and MS patients did not differ as both 
absolute numbers and percentage with respect to total PBMCs. 
Interestingly, the results show that DRs expression was not differ-
ent between MS patients and HC in any of the subsets of DCs ana-
lysed, both at the level of number of cells expressing the receptors 
or at the level of DRs density in the cell surface (Figures 5A–C). 
Nevertheless, the results show an important increase in the abso-
lute number of NCl-Mo expressing all five DRs in the cell surface 
(Figure 5D). This increase in NCl-Mo expressing DRs was associ-
ated with enhanced counts of NCl-Mo in peripheral blood and 
an augmented proportion of this monocyte subset in the total 
FigUre 5 | Dopamine receptor D5 (DRD5) expression is selectively increased in peripheral blood plasmacytoid and myeloid dendritic cells (DCs) obtained from MS 
patients. Fresh blood samples were obtained from healthy subjects (HS, n = 10; white bars) or multiple sclerosis patients (MS, n = 9; striped bars), and the 
expression of DRs (D1-like and D2-like) was analysed in different cell populations as the numbers of cells expressing each receptors (left panels) or the MFI 
associated with the immunostaining of each receptor (right panels). The expression of DRs in total peripheral blood DCs (BDCs) (a), plasmacytoid DCs (pDCs) (B), 
and myeloid DCs (mDCs) (c) were analysed based on the gating strategy described in Figure S9 in Supplementary Material. The expression of DRs in non-classical 
monocytes (NCl-Mo) (D) were analysed based on the gating strategy described in Figure S10 in Supplementary Material. Values represent mean ± SEM. *p < 0.05; 
**p < 0.01 by unpaired two-tailed Student’s t-test.
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population of peripheral blood monocytes (Table 2). Moreover, 
the increased number of monocytes expressing DRs was selec-
tive to NCl-Mo, as the counts for Cl-Mo and Int-Mo expressing 
DRs did not differ between HC and MS patients (Figure S11 in 
Supplementary Material). The density of surface DRs expression 
was similar between HC and MS patients in all the monocytes 
subsets analysed (Figure  5D; Figure S12 in Supplementary 
Material). Thus, the overall analysis of DRs expression in APCs 
obtained from human individuals indicates a selective increase 
of the inflammatory subset of monocytes expressing all DRs in 
MS patients.
DiscUssiOn
Early studies addressing the role of dopamine in the physi-
opathology of MS showed deregulated production of catecho-
lamines and altered expression of a number of components of 
the dopaminergic system in PBMCs obtained from MS patients 
(33, 34). Subsequent studies analysing the role of dopaminergic 
alterations in MS patients confined to T-cells revealed an associa-
tion of MS manifestation with the capability of Tregs to produce 
and respond to dopamine in a DRD5-dependent manner (35). In 
this regard, it has been described that human Tregs are capable 
to produce dopamine and, upon release of this mediator, sup-
pressive activity is abolished by a DRD5-dependent mechanism 
(51). Importantly, both DRD5 expression and the capability to 
synthesise dopamine are exacerbated in untreated MS patients, 
thus reducing the anti-inflammatory function of Tregs. However, 
it has been shown that the treatment of MS patients with IFN-β 
reduces the levels of DRD5 and abolishes the expression of the 
machinery required to synthesise dopamine in Tregs, thus re-
establishing their suppressive activity (35). Thereby, Tregs seem 
to be key players in the dopaminergic regulation of inflammation 
in the physiopathology of MS. In the present study, we described 
myeloid APCs as another key player of the dopaminergic 
regulation of immunity, which seems to play an important role 
promoting the inflammatory response in EAE and MS by a 
DRD5-dependent mechanism. Of note, our findings described 
here together with previous evidence indicate that DRD5-driven 
effects in different types of immune cells promote inflammation, 
supporting the idea that DRD5 results a key molecular target to 
limit autoimmunity.
It is important to consider that in our study, we included 
just a small sample size of MS patients and healthy individuals, 
which had the purpose of exploring whether the pro-inflam-
matory effect of DRD5-signalling observed in mouse APCs in 
the context of EAE was equivalent in human APCs obtained 
from MS patients. Due to the high difficulty of obtaining sam-
ples from untreated MS patients, we used here blood samples 
obtained from IFN-β-treated patients. To rule out the pos-
sibility that IFN-β treatment affected the frequency of different 
subsets of myeloid cells and/or the expression of functionally 
relevant molecules in these cells, we analysed these parameters 
and observed similar frequencies of DCs subpopulations and 
expression of HLA-DR when samples from MS patients were 
compared with HS (Figures S11 and S12 in Supplementary 
Material; Table 2). The only significant difference detected in 
our analyses carried out in blood samples obtained from MS 
patients was that their inflammatory subset of monocytes was 
increased and displayed a stronger frequency of DRs expression 
in comparison with healthy individuals (Figure 5D). It is note-
worthy that this observation agrees with the pro-inflammatory 
role of DRD5-signalling described here in mouse myeloid APCs 
in the context of EAE.
In agreement with our findings described here, a previous 
study demonstrated that the systemic administration of the 
D1-like antagonist SCH23390 reduces the clinical manifestation 
of EAE in SJL/J mice immunised with a peptide derived from 
myelin proteolipid protein (52). Similarly, subsequent studies 
have shown that D1-like antagonism attenuates the inflammatory 
response in collagen-induced arthritis (53, 54), allergic asthma 
(55, 56), diabetes (57), and nephrotoxic serum nephritis (58). 
Mechanistic analyses have suggested that the therapeutic effect 
exerted by SCH23390 in these inflammatory disorders is due to 
D1-like antagonism in both CD4+ T-cells and DCs. The evidence 
suggests that D1-like DRs-signalling in CD4+ T-cells promotes 
B-cell activating transcription factor activity, favouring RAR-
related orphan receptor gamma upregulation and consequently 
Th17-mediated responses, which is inhibited by SCH23390 (56). 
Conversely, the molecular mechanism by which this drug attenu-
ates the inflammatory potential of DCs has been poorly explored. 
We demonstrated that the anti-inflammatory effect of D1-like 
antagonism in DCs was due to the inhibition of DRD5-signalling, 
which is coupled to the attenuation of STAT3 phosphorylation 
(Figure 3) and the consequent potentiation in IL-12 and IL-23 
production (37).
Here, we show that DRD5-signalling dampens the phos-
phorylation of STAT3 triggered by LPS stimulation in DCs 
(Figures  2–4). Importantly, STAT3-activation has been 
involved in the repression of both IL-12 and IL-23 (10, 11). 
In agreement with these observations, our previous results 
have shown that DRD5-signalling in DCs favours selectively 
the production of the inflammatory cytokines IL-12 and IL-23, 
without effect in the secretion of IL-10, IL-6, IL-1β, and TGF-β 
(29, 37). Furthermore, in the present study our data indicate 
that DRD5-signalling confined to DCs strengthens Th1- and 
Th17-mediated immunity and the participation of GM-CSF-
producing CD4+ T-cells in  vivo (Figure  1), responses that 
depend on IL-12 and IL-23 activity (6, 7, 14). It is noteworthy 
that even if we trigger EAE development by immunisation 
with pMOG/CFA, the phenotype of encephalytogenic T-cells 
was evaluated by intracellular cytokine staining of T-cells 
after ex vivo restimulation by a polyclonal stimulus (PMA plus 
ionomycin) instead an antigen-specific stimulus (pMOG). In 
this regard, is has been shown that chronic progression of EAE 
is invariably linked to the process of epitope-spreading, which 
involves a shift of T-cell specificity from the initial immunogen 
(pMOG in this case) to others relevant CNS-derived auto-
antigens (59). Thereby, to avoid an underestimation of the 
frequency associated with each encephalytogenic T-cell subset, 
we analysed polyclonal T-cells rather than pMOG-specific 
T-cells infiltrating the CNS.
Regarding the signalling pathways coupled to DRD5 in DCs, 
in a previous report we showed that DRD5-stimulation in DCs 
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was coupled to the inhibition of ERK1/2-activation triggered by 
LPS (37). To address how DRD5-signalling was related with the 
decrease of ERK1/2-activation and the attenuation of STAT3-
phosphorylation, we determined whether DRD5-stimulation was 
coupled to cAMP production in DCs, as cAMP has been involved 
in the attenuation of both ERK1/2 and STAT3 pathways in breast 
cancer cells (60, 61). In agreement with most reports addressing 
the coupling of DRD5 in different cell types (46), our results 
suggest that DRD5-stimulation in DCs was also coupled with 
the induction of cAMP production (Figure S1 in Supplementary 
Material). Thereby, it is tempting to speculate that cAMP trig-
gered by DRD5-stimulation in DCs is a mediator responsible for 
the down-stream inhibition of ERK1/2 and STAT3 activation 
observed. In addition, previous studies have shown that ERK1/2 
may potentiate the activation of STAT3 (62), suggesting that 
DRD5-mediated inhibition of ERK1/2 may also contribute in the 
reduction of STAT3-phosphorylation observed when DRD5 is 
stimulated in DCs.
Despite it is likely that LPS and IL-6 lack relevance as induc-
ers of STAT3-activation in DCs in the in vivo context of EAE and 
MS, they are useful tools for in vitro experiments. Conversely, 
it is more probable that IL-10 produced by suppressive subsets 
of lymphocytes as well as CTLA4 interaction with B7 molecules 
are more relevant actors as inducers of STAT3-activation in 
the context of EAE and MS. In this regard, IL-10 produced by 
Tregs or by a suppressive subset of B-cells, B10 cells, has been 
shown to induce STAT3-activation in DCs and to play a relevant 
anti-inflammatory role dampening EAE manifestation (10, 63, 
64). On the other hand, it has been reported that the B7-ligand 
CTLA4, which is expressed in Tregs surface, triggers STAT3-
phosphorylation in DCs inducing a tolerogenic behaviour 
(65). In addition, it has been described that activated STAT3 
may inhibit the recruitment of NF-κB to the promoter of p40 
(10), a common subunit for IL-12 and IL-23. Moreover, it has 
also been reported that STAT3 activation may prevents the 
recruitment of the positive transcription elongation factor b to 
the promoter of IL-12p35 (11). Thus, previous evidence agrees 
with the tolerogenic effect of STAT3 observed here in DCs in 
the context of EAE.
An intriguing question about of dopaminergic-mediated 
regulation of immunity is what is the relevant source of this neu-
rotransmitter to exert an effect on immune cells. In this regard, 
it is necessary to consider the spatiotemporal redistribution of 
immune cells during the development of the disease. In the case 
of EAE, APCs play important roles twice during the time-course 
of the disease, being involved first in the peripheral activation of 
CD4+ T-cells and later in the re-stimulation of T-cells inside the 
CNS (66). It is noteworthy that in the CNS, CD4+ T-cells may be 
restimulated by resident APCs, such as astrocytes or microglia, 
as well as by APCs infiltrating from the periphery such as DCs 
and monocytes/macrophages (67). Moreover, a previous work 
has shown a rise of dopamine levels in the striatum during the 
onset and the peak of EAE manifestation (32). Despite there 
is not direct evidence showing that DCs might infiltrate the 
striatum during the onset or the peak of EAE manifestation, 
this data suggests that dopamine produced in the CNS could 
represent a relevant source for the dopaminergic regulation of 
the immune response involved in this disorder. On the other 
hand, previous studies described that DCs can synthesise and 
store dopamine (29, 36, 37), thus suggesting that these cells may 
represent a source of this mediator available for immune cells in 
close proximity, including themselves. Here, we addressed the 
question of whether dopamine contained inside DCs is a relevant 
source of this neurotransmitter to trigger the pro-inflammatory 
behaviour of DCs mediated by DRD5-signalling. Our results 
here show a relevant and potent effect of DCs-derived dopamine 
in the stimulation of DRD5–STAT3 axis in vivo, favouring the 
development of EAE (Figure  3). Nevertheless, these results 
does not rule out the possibility that the rise of dopamine in 
the CNS during the onset and the peak of EAE manifestation 
plays a relevant role in the regulation of immunity during 
the development or progression of the disease. Furthermore, 
increasing evidence has demonstrated a constitutive activity 
of G-protein coupled receptors, including DRD5, which exerts 
physiologically relevant roles even in the absence of endogenous 
ligands (68). Thereby, these studies suggest that basal signalling 
triggered by DRD5 could contribute to the pro-inflammatory 
behaviour in DCs irrespective of the availability of dopamine 
for these cells.
In conclusion, the present study suggests a mechanism 
by which DRD5-signalling in myeloid APCs strengthens 
the inflammatory response mediated by self-reactive CD4+ 
T-cells in EAE. This mechanism involves an autocrine loop 
in which DCs-derived dopamine stimulates DRD5-signalling 
and the down-stream attenuation of STAT3-activation. Our 
data indicate that targeting this mechanism at different levels, 
a significant therapeutic effect was reached, including the 
depletion of DCs-derived dopamine, DRD5-antagonism or 
desensitising STAT3-inhibition in DCs. Furthermore, the 
analysis performed in human individuals indicated a selective 
and significant increase of dopaminergic signalling in inflam-
matory monocytes in MS patients. Thus, these results suggest an 
equivalent pro-inflammatory role of DRD5–STAT3 axis exerted 
by BM-DCs in EAE in mouse and by inflammatory monocytes 
in MS in human. Taken together, our findings describe a novel 
therapeutic target to dampen the inflammatory T-cell response 
in EAE with promising clinical potential for MS.
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